HC Wainwright Has Negative Outlook for FENC Q1 Earnings

Adherex Technologies Inc. (NASDAQ:FENC) – Stock analysts at HC Wainwright decreased their Q1 2026 EPS estimates for Adherex Technologies in a report released on Monday, March 30th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.02) for the quarter, down from their previous forecast of $0.07. The consensus estimate for Adherex Technologies’ current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Adherex Technologies’ Q2 2026 earnings at $0.05 EPS, FY2026 earnings at $0.31 EPS, Q1 2027 earnings at $0.17 EPS and Q2 2027 earnings at $0.22 EPS.

Adherex Technologies (NASDAQ:FENC) last announced its quarterly earnings results on Friday, March 27th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.21). The business had revenue of $13.78 million for the quarter, compared to analysts’ expectations of $14.75 million. Adherex Technologies had a negative net margin of 22.62% and a negative return on equity of 183.18%.

FENC has been the subject of a number of other reports. Zacks Research lowered Adherex Technologies from a “hold” rating to a “strong sell” rating in a report on Wednesday, March 25th. Piper Sandler began coverage on Adherex Technologies in a research note on Friday, January 9th. They set an “overweight” rating and a $18.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Adherex Technologies in a report on Thursday, January 22nd. B. Riley Financial began coverage on Adherex Technologies in a research note on Thursday, February 12th. They issued a “buy” rating and a $16.00 target price for the company. Finally, Wall Street Zen lowered Adherex Technologies from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $15.25.

Adherex Technologies Trading Up 4.2%

Adherex Technologies stock opened at $6.41 on Wednesday. The firm has a 50 day simple moving average of $7.75 and a 200 day simple moving average of $8.03. Adherex Technologies has a 1-year low of $4.68 and a 1-year high of $9.92. The firm has a market capitalization of $220.95 million, a price-to-earnings ratio of -18.85 and a beta of 0.93.

Insider Activity at Adherex Technologies

In other news, Director Rosty Raykov sold 10,349 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $7.76, for a total value of $80,308.24. Following the transaction, the director owned 98,477 shares of the company’s stock, valued at approximately $764,181.52. This represents a 9.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 11.76% of the stock is owned by company insiders.

Institutional Investors Weigh In On Adherex Technologies

An institutional investor recently bought a new position in Adherex Technologies stock. AQR Capital Management LLC purchased a new position in Adherex Technologies Inc. (NASDAQ:FENC) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 10,897 shares of the company’s stock, valued at approximately $66,000. Institutional investors own 55.51% of the company’s stock.

Adherex Technologies News Roundup

Here are the key news stories impacting Adherex Technologies this week:

• Positive Sentiment: HC Wainwright projects strong longer‑term profitability, forecasting FY2027 EPS of $0.96 and several positive quarterly EPS estimates for 2027 — a bullish long‑term signal for growth expectations. Read More.
• Positive Sentiment: Street consensus remains constructive — analysts have issued a “Moderate Buy” recommendation on FENC, which can support demand for the shares. Read More.
• Neutral Sentiment: The company granted inducement stock options (ISOs) to 24 new non‑executive employees totaling 377,500 shares under its 2026 Inducement Plan; this is intended to attract talent but introduces potential dilution over time. Read More.
• Negative Sentiment: Recent quarterly results disappointed: Adherex reported a ($0.17) EPS vs. consensus +$0.04 and revenue of $13.78M vs. $14.75M expected — a clear near‑term negative that can pressure the stock. Read More.
• Negative Sentiment: HC Wainwright trimmed several near‑term estimates (multiple 2026 quarters and FY2026 EPS cut from $0.64 to $0.31) — the broker lowered short‑term expectations even while keeping a more optimistic FY2027 view, creating mixed signals that can add volatility. Read More.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.